Trial Profile
Multicenter Double Blind Randomized Phase II Trial of Olaparib vs Placebo as Maintenance Therapy in Platinum-sensitive Advanced Endometrial Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 08 Dec 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- Acronyms GINECO-UTOLA; UTOLA
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Primary endpoint (Efficacy: Progression free survival (PFS1) according to modified Response Evaluation Criteria in Solid Tumors (RECIST version 1.1) of Olaparib maintenance after a platinum based chemotherapy in patients with advanced or metastatic endometrial cancer) has not been met, according to Results presented at the 48th European Society for Medical Oncology Congress.
- 06 Sep 2021 Status changed from recruiting to active, no longer recruiting.